small percentage of the total cells in most samples such that clinical laboratory clonality studies are usually negative.
The BIOMED-2 primers showed roughly equivalent clinical sensitivity for fresh and paraffin-embedded tissue samples. In general, the number of positive peaks was fewer, and the height of positive peaks less, in the paraffin samples compared with the corresponding fresh samples. However, this pattern was reversed in a small number of samples. The apparent overall increase in clinical sensitivity using paraffin tissue in this study (Table 1) is likely due to the fact that many of the negative fresh samples had inadequate paraffin samples to evaluate due to the retrospective study design; many of the paraffin samples had been pretreated with B5, a heavy metal fixative that is used to improve cell histology, but inhibits PCR reactions. However, in our clinical experience with freshly-embedded, non-B5 fixed samples, the majority are adequate for analysis.
Maximum sensitivity was obtained when both IGH and IGK were evaluated (Table 1) . In all, 60% of positive samples showed positivity in more than one size range. Primers in IGH tubes D and E produced positivity in the fewest number of samples and were rarely the sole positive primer groups (D tube positive 24% and sole positive 3%; E tube positive 1% and sole positive 0%). Thus, the true contribution to sensitivity of the primers in the IGH D and E tubes will require more extensive evaluation. The IGL primers did not appear to add sensitivity as all neoplastic samples found negative following evaluation of IGH and IGK were tested using the IGL primers without additional positive samples being detected. The distribution of primer positivity is similar to that reported in the original validation studies. 3 Clinical specificity was 100% with all 64 normal and reactive samples being negative. However, many of these samples showed a large reactive peak in the smallest size range of the IGK A tube primers, which could easily be misinterpreted as a clonal peak. After careful review of the entire data set, it was noted that true positive peaks in the range of concern were distinctive, originating from the baseline without associated polyclonal background, but reactive peaks were less defined and always associated with some degree of polyclonal background ( Figure 3 ). Despite this distinction, extreme caution should be used when apparent true positivity is identified only in this size range. We feel that such isolated peaks should be considered equivocal, particularly in the absence of data from other diagnostic methods for correlation.
Analytical sensitivity was at least 1% in a T-cell rich (thymus) background but was only 30% in a B-cell rich (tonsil) background. In addition, the presence of a limited amount of IG DNA in the sample (limited template) could not be shown to produce false-positive peaks.
In conclusion, the BIOMED-2 primers for PCR-based evaluation of IG gene rearrangements performed very well in this independent validation study and the study significantly expand published validation data for these primers. For most clinical applications, sensitivity should be essentially 100%, as the neoplasm groups showing o100% sensitivity rarely require IG gene rearrangement analysis for diagnosis. However, analysis of both IGH and IGK is required for optimal sensitivity. Clinical specificity was found to be 100%. The antimetabolite cytosine arabinoside (Ara-C) is a deoxycytidine analog that is used as a therapeutic agent in many leukemia treatment regimens. In combination with anthracyclines, Ara-C is the most effective agent in the treatment of acute myeloid leukemia (AML). In the treatment of acute lymphoblastic leukemia (ALL), the use of Ara-C is limited. However, leukemic cells from infants (o1 year of age) with ALL, which are resistant to several chemotherapeutic drugs, are in vitro more sensitive to Ara-C as compared to older children with ALL. 1, 2 This observation suggested that infant ALL might resemble a subclass of childhood ALL, which may benefit from intensified treatment with Ara-C to improve the dismal prognosis for these patients who to date experience an event-free survival (EFS) of B35%. Therefore, in 1999, a novel collaborative treatment protocol (INTERFANT-99) was designed with intensified use of Ara-C, in order to provide a more specific treatment to infant ALL patients.
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Ara-C mainly depends on the human equilibrative nucleoside transporter 1 (ENT1) to permeate the cell membrane. Inside cells, the prodrug Ara-C is phosphorylated into its active, cytotoxic form Ara-CTP, as which it competes with dCTP for incorporation into DNA. When incorporated, Ara-C blocks DNA synthesis and induces apoptosis (Figure 1 ). Ara-C is phosphorylated by deoxycytidine kinase (dCK) to form Ara-CMP. Subsequently, Ara-CTP is formed by two additional phosphorylations catalyzed by (deoxy)cytidylate kinase (UMP-CMPK) and nucleoside diphosphate kinases (NDKs), respectively (Figure 1 ). Several enzymes, however, oppose the formation of functional Ara-CTP and thus the cytotoxic effects of this drug. Pyrimidine nucleotidase I (PN-I), for example, preferentially dephosphorylates Ara-CMP to Ara-C. 3 Cytidine deaminase (CDA) and deoxycytidylate deaminase (dCMPD) convert Ara-C to Ara-U and Ara-CMP to Ara-UMP, respectively, by deamination of the cytosine base of Ara-C. Recently, we demonstrated that Ara-C sensitivity in infant ALL is related to increased expression of ENT1 (responsible for Ara-C transport across the cell membrane 4 ) and not to the expression of other genes involved in Ara-C metabolism (mentioned above).
Infant ALL is characterized by rearrangements of the Mixed Lineage Leukemia (MLL, ALL-1, or HRX) gene on chromosome band 11q23, in approximately 80% of the cases. The most common translocations involving MLL in infant ALL are t(4;11)(q21;q23) and t(11;19)(q23;p13.3) resulting in a fusion of MLL with AF-4 on chromosome 4 and ENL on chromosome 19, respectively. In childhood AML, MLL gene rearrangements are mainly restricted to the FAB M4 and M5 subtypes, and occur in the majority of the infant cases. Interestingly, childhood M4/M5 AML harboring t(9;11)(q22;q23) in which MLL is fused to AF-9 on chromosome 9 has also been reported to be highly sensitive to Ara-C when compared to other AML subtypes without MLL rearrangements. 5 The fact that Ara-C sensitivity is found in both MLL rearranged infant ALL and MLL rearranged M4/M5 AML, raises an important question: is Ara-C sensitivity (or increased expression of ENT1) directly associated with rearrangements of the MLL gene? To answer this question, we set out to determine the relationship between Ara-C sensitivity, expression of Ara-C metabolizing enzymes, and the presence of MLL gene rearrangements in both infant ALL and pediatric AML M4/M5. Patient characteristics are listed in Table 1 .
The MTT-assay was used to determine in vitro Ara-C cytotoxicity. Within infant ALL, no significant difference in Ara-C sensitivity was found between MLL rearranged (MLL þ ) and MLL germline (MLL -) infant ALL cases (Figure 2a) . Furthermore, no differences in Ara-C sensitivity were observed between infant ALL patients harboring either translocation t(4;11) or t(11;19) and MLL germline cases (Figure 2b) . Also, no statistically significant difference in Ara-C cytotoxicity was observed between MLL þ and MLL À AML M4/M5 cases (Figure 3a) , nor between AML M4/M5 patients carrying t(9;11) or other translocations involving MLL (11q23) and AML M4/M5 patients carrying germline MLL genes (Figure 3b) .
The relative mRNA expression levels of ENT1, dCK, PN-I, CDA and dCMPD was measured using quantitative real-time PCR (TaqMan) as described before. 4 The expression of genes important for membrane transport and for the metabolism of Ara-C into its active, cytotoxic form Ara-CTP did not significantly differ between MLL -and MLL þ infant ALL cases (Table 2) , nor between MLL À and MLL þ M4/M5 AML cases ( Table 3 ). The only exception was PN-I, which was expressed significantly higher in infant ALL patients carrying germline MLL genes than in MLL þ infant ALL samples (Table 2 ). This would be in line with the hypothesis that MLL rearrangements induce Ara-C Figure 1 Ara-C metabolism. Ara-C enters the cell mainly via 1 equilibrative nucleoside transporter 1 (hENT1) and is subsequently phosphorylated to Ara-CMP by 2 deoxycytidine kinase (dCK), followed by two more phosphorylation steps catalyzed by (deoxy)cytidylate kinase (UMP-CMPK) and nucleoside diphosphate kinases (NDKs), respectively, to form Ara-CTP. Incorporation of Ara-CTP into the DNA during DNA synthesis leads apoptosis. Ara-CTP formation can, however, be obstructed 3. Pyrimidine nucleotidase I (PN-I) inhibits Ara-CTP formation by opposing the action of dCK 4. Cytidine deaminase (CDA) and 5 deoxycytidylate deaminase (dCMPD) both are inactivating enzymes, which convert Ara-C to Ara-U and Ara-CMP to Ara-UMP, respectively, thereby decreasing the amount of functional Ara-CTP that can be formed. 11q23 indicates translocations involving MLL other than t(4;11), t(11;19), or t(9;11).
Letters to the Editor sensitivity, as this would imply that increased dephosphorylation of Ara-CMP leads to increased resistance to Ara-C in leukemic cells from infant ALL patients carrying germline MLL. However, this increased PN-I expression does not seem to affect Ara-C sensitivity in these patients, as no significant difference in Ara-C cytotoxicity could be observed between both patient groups ( Figure 2) .
Our finding that Ara-C sensitivity is not directly associated with the presence of MLL rearrangements is in agreement with our recent study. 2 No apparent differences in Ara-C sensitivity were found between MLL À and MLL þ ALL cases o1 year of age, nor between MLL À and MLL þ ALL above this age. 2 Moreover, the same study further demonstrated no statistical differences in Ara-C cytotoxicity between t(4;11) positive ALL samples and samples carrying other translocations involving MLL. 2 Furthermore, it appeared that among ALL patients X1 year of age, pro-B (CD10 -, CD19 þ ) cases are more sensitive to Ara-C as compared to common (CD10 þ , CD19 þ ) and pre-B Figure 2 Ara-C cytotoxicity in infant ALL. In vitro Ara-C cytotoxicity (LC 50 Ara-C in mg/ml) in (a) leukemic cells from MLL gene rearranged (n ¼ 26) and MLL germline (n ¼ 8) infant ALL patients (Mann-Whitney U-test) and (b) leukemic cells from infant ALL patients carrying translocation t(4;11) (n ¼ 16) or t(11;19) (n ¼ 10), or germline MLL (n ¼ 8) (Kruskal-Wallis test).
Figure 3
Ara-C cytotoxicity in childhood M4/M5 AML. In vitro Ara-C cytotoxicity in (a) leukemic cells from MLL gene rearranged (n ¼ 14) and MLL germline (n ¼ 13) childhood M4/M5 AML patients (Mann-Whitney U test) and (b) in cells from childhood M4/M5 AML patients carrying translocation t(9;11) (n ¼ 8) or unknown translocation involving MLL (11q23) (n ¼ 6), or germline MLL (n ¼ 13) (KruskalWallis test).
Table 2
Comparison of expression levels of Ara-C metabolizing enzymes between infant ALL patients with and without MLL gene rearrangements Letters to the Editor (CD19 þ , CyIgm þ ) ALL cases. However, in infant ALL patients (o1 year of age) the pro-B phenotype was not associated with sensitivity to Ara-C, but the number of infants with pre-B or common phenotypes was small. 2 Thus, Ara-C sensitivity in ALL seems to be associated with age (i.e. o1 year) and immunophenotype, but not with the presence of MLL rearrangements. Possibly, sensitivity to Ara-C as observed in childhood AML M4/M5 cells is associated with the M4/M5 FAB type rather than with young age.
In conclusion, the present study does not provide data to support that MLL rearrangements are directly involved in the increased sensitivity to Ara-C as detected in infant ALL and M4/M5 AML.
The JAK-STAT pathway is a central mediator of cytokine signaling in hematopoietic cells, and its deregulation has been observed in human hematological and solid malignancies. The notion that JAK-STAT signaling may drive tumor formation has been strengthened by the identification of JAK2 genetic alterations in human leukemia. Initially, we and others have identified fusions of the JAK2 gene with the TEL(ETV6) gene in cases of human childhood T-cell acute lymphoblastic leukemia (ALL), pre-B ALL and atypical chronic myeloid leukemia (CML). 1, 2 More recently, JAK2 fusions with the PCM1 and BCR genes have also been identified in CML and pre-B ALL. 3, 4 In addition, a frequent JAK2 point mutation (JAK2 V617F ) has been identified in human clonal myeloproliferative disorders. 5 Both the TEL-JAK2 fusion and the JAK2 V617F mutation result in constitutive JAK2 tyrosine kinase activity.
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